Description
This variant is denoted BRCA2 c.551T>C at the cDNA level, p.Leu184Pro (L184P) at the protein level, and results in the change of a Leucine to a Proline (CTA>CCA). Using alternate nomenclature, this variant would be defined as BRCA2 779T>C. This variant was observed in a Japanese woman with epithelial ovarian cancer, in three other Japanese individuals referred for BRCA1/2 testing, and in an individual with pancreatic cancer (Sekine 2001, Arai 2017, Takeuchi 2018). This variant was reported to not increase exon skipping in a minigene reporter assay (Di Giacomo 2013). BRCA2 Leu184Pro was not observed in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether BRCA2 Leu184Pro is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
# | Sample | Method | Observation |
---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
---|
1 | germline | yes | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |